Q-omics provides the consensus-scored ZNF207 profile across patient tissues and cancer cell-line models. ZNF207 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, ZNF207 is differentially expressed in 16, with the highest sampling consensus in KIRC. Additionally, ZNF207 protein abundance shows 27,871 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, KIRC, and LSCC as cancer lineages where ZNF207 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF207 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF207 survival associations across molecular data types. ZNF207 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (3) and mass-spec protein abundance (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF207 RNA expression–survival associations across cancer types. High ZNF207 expression shows unfavorable associations in ACC, LIHC, MESO, KIRP and KICH, but favorable associations in UCS. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for ZNF207 RNA expression.
This table summarizes ZNF207 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 10. The strongest signals are observed in KIRC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for ZNF207. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF207 shows higher tumor expression in KIRC, COAD, BLCA, KIRP, LUAD and HNSC. The KIRC box plot shows higher ZNF207 RNA expression in tumor versus normal tissue (log2 FC = +0.454, t-test p < 0.001).
This table shows molecular features associated with ZNF207 in patient tissues and cancer cell lines. In patient samples, ZNF207 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF207 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and UPPER_AERODIGESTIVE_TRACT.
